MeCP2 Dosage Control in Rett Syndrome: Non-Coding RNA-Based and Epigenetic Strategies for Safer Gene Therapy

Description

Ilyas M Kabdesh, Albert A Rizvanov, and Yana O Mukhamedshina review gene therapy design for Rett syndrome in a 2026 article. The disorder stems from faults in MECP2, a gene whose protein must sit in a narrow dose window: too little or too much both wreck the brain. That sensitivity makes plain gene replacement by virus risky. The review surveys control systems that could keep a replacement gene on a leash.

Options include promoters borrowed from the gene itself, cell-specific switches, and microRNA elements that trim output in the wrong cells. Self-regulating designs let the transgene sense and correct its own level. A bolder route wakes the healthy copy silenced on the second X chromosome, using XIST-based control or direct epigenome editing. CRISPR-based tuning and combined platforms layer these brakes together. The authors judge that safe Rett therapy will need several such layers at once.

Catalog record

Source: https://europepmc.org/article/MED/PMC13516522